Medication info

Ilyang Zenta Duo Tablet 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Ilyang Pharmaceutical Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablet
Packaging
30 tablets/box [6 tablets/PTP x 5]
Approval status
Expired

MFDS item code 202003644 · Approved 2020.05.19

This product's status changed to Expired on 2025.05.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients inadequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have been conducted to assess the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in type 2 diabetes treatment may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Ilyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is developed to assist patients with type 2 diabetes in controlling blood glucose levels by combining linagliptin and metformin. Taking this medication alongside dietary management and exercise can help manage blood glucose more effectively. Therefore, it is used as an important adjunct in diabetes treatment.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients inadequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have been conducted to assess the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in type 2 diabetes treatment may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication may cause a serious side effect known as lactic acidosis, so it should not be used in patients with severely impaired kidney function, hepatic dysfunction, acute infections, or heart disease. Patients who are allergic to any of the active ingredients, those with type 1 diabetes, and pregnant or nursing women should also refrain from taking this medication. Due to the risk of hypoglycemia, blood glucose should be carefully monitored when used in conjunction with insulin or sulfonylureas. To reduce the risk of lactic acidosis, this medication should be temporarily discontinued in cases of dehydration, severe vomiting, or diarrhea, and symptoms should be reported to a physician immediately. In cases of diminished kidney function, kidney function should be regularly monitored through blood tests, and the medication should be discontinued if there is concern about acute kidney failure. This medication should be discontinued before and after surgeries or when undergoing radiographic iodine contrast examinations, and resuming the medication should occur only after renal function has returned to normal. Long-term use of this medication may reduce vitamin B12 levels; therefore, if anemia or neurological symptoms occur, vitamin B12 testing should be conducted. If symptoms of acute pancreatitis or blistering dermatosis appear, discontinue the medication and consult a physician. In the elderly, decreased kidney function is common, so dose adjustments and regular monitoring of renal function should be performed. Pregnant women or those planning to become pregnant should preferably avoid this medication, and breastfeeding women should also avoid use. This medication may interact with other drugs; thus, it is crucial to inform the healthcare provider or pharmacist of any other medications being taken. In the event of an overdose, the risk of lactic acidosis is present, and immediate hospital treatment is necessary, which may include hemodialysis. Store out of reach of children and protect from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • gustatory dysfunction
  • cough
  • decreased appetite
Show 108 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blister-like pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • bowel obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pruritus
  • anxiety
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • epigastric pain
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • dizziness
  • headache
  • drowsiness
  • chest discomfort
  • weakness
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and must be stored in a tightly sealed container. Additionally, it should be stored at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablet

Package unit

30 tablets/box [6 tablets/PTP x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.